Form 4: Regeneron Executive Boosts Stake with Equity Awards

Regeneron Pharmaceuticals executive Daniel P. Van Plew received significant equity awards, including restricted stock and stock options, while also disposing of shares for tax purposes.

Summary

• Daniel P. Van Plew, EVP & General Manager, Industrial at Regeneron Pharmaceuticals, Inc. (REGN), reported changes in his beneficial ownership.
• On December 5, 2025, Mr. Van Plew acquired 3,715 shares of Common Stock as a Restricted Stock Award under the Second Amended and Restated 2014 Long-Term Incentive Plan.
• This Restricted Stock Award vests 50% on December 5, 2027, and the remaining 50% on December 5, 2029.
• Also on December 5, 2025, he was granted 18,315 Non-Qualified Stock Options with an exercise price of $726.71.
• These stock options vest in four equal annual installments, commencing one year after the grant date (December 5, 2026), and expire on December 5, 2035.
• On December 8, 2025, Mr. Van Plew disposed of 1,906 shares of Common Stock at a price of $712.94 per share, likely for tax withholding purposes (Transaction Code 'F').
• Following these transactions, Mr. Van Plew directly owns 24,225 shares of Common Stock and 18,315 Non-Qualified Stock Options.
• He also indirectly owns 12,376 shares through a 2025 GRAT and 1,129 shares through a 401(k) Plan.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the executive receiving substantial equity awards, indicating continued alignment with company performance and long-term commitment. The disposition of shares is likely tax-related and does not significantly detract from the overall positive signal of the awards.

Positives

• The executive's receipt of significant equity awards (restricted stock and stock options) aligns his interests with long-term shareholder value.
• The vesting schedules for both the restricted stock (through 2029) and stock options (through 2029) incentivize sustained performance and retention of key management.

Negatives

• The disposition of 1,906 shares, while likely tax-related, represents a reduction in direct beneficial ownership.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Increased alignment of executive incentives with long-term shareholder value through equity awards.
• Employees: The equity awards demonstrate the company's strategy for executive retention and motivation.

Next Steps

• Vesting of 50% of Restricted Stock Award on December 5, 2027.
• Vesting of remaining 50% of Restricted Stock Award on December 5, 2029.
• Annual vesting of Non-Qualified Stock Options, commencing December 5, 2026, over four years.

Key Dates

Keywords

Regeneron Pharmaceuticals, REGN, Insider Transaction, Form 4, Restricted Stock Award, Stock Options, Executive Compensation, Equity Grant, Beneficial Ownership